Martin  Mackay net worth and biography

Martin Mackay Biography and Net Worth

CEO of Rallybio
Martin is a Co-Founder and Chief Executive Officer of Rallybio and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca, and Alexion. He is currently a member of the Board of Directors of Charles River Laboratories, Novo Nordisk, and the 5.01 Acquisition Company. He is also a Senior Advisor at New Leaf Ventures. Martin summarizes the three loves in his life as being family, work, and soccer, but not necessarily in that order.

Martin obtained a First-Class Honours Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.

OTHER THINGS WORTH KNOWING ABOUT ME:

When I’m not working, I’m playing soccer, boating, ballroom dancing, training my GSD, and hanging with my grandchildren, Charlie and Sophie.

My favorite sports team is the Heart of Midlothian Football Club.

My greatest non-work accomplishment is still playing competitive soccer at 63.

What is Martin Mackay's net worth?

The estimated net worth of Martin Mackay is at least $79,006.10 as of May 16th, 2016. Dr. Mackay owns 42,706 shares of Rallybio stock worth more than $79,006 as of March 28th. This net worth approximation does not reflect any other assets that Dr. Mackay may own. Learn More about Martin Mackay's net worth.

How do I contact Martin Mackay?

The corporate mailing address for Dr. Mackay and other Rallybio executives is , , . Rallybio can also be reached via phone at 203-59-3820 and via email at [email protected]. Learn More on Martin Mackay's contact information.

Has Martin Mackay been buying or selling shares of Rallybio?

Martin Mackay has not been actively trading shares of Rallybio during the last quarter. Most recently, on Monday, January 10th, Martin Mackay bought 5,504 shares of Rallybio stock. The stock was acquired at an average cost of $10.10 per share, with a total value of $55,590.40. Learn More on Martin Mackay's trading history.

Who are Rallybio's active insiders?

Rallybio's insider roster includes Jeffrey Fryer (Insider), Martin Mackay (CEO), and Stephen Uden (Insider). Learn More on Rallybio's active insiders.

Martin Mackay Insider Trading History at Rallybio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2022Buy5,504$10.10$55,590.40View SEC Filing Icon  
See Full Table

Martin Mackay Buying and Selling Activity at Rallybio

This chart shows Martin Mackay's buying and selling at Rallybio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rallybio Company Overview

Rallybio logo
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $1.85
Low: $1.59
High: $1.86

50 Day Range

MA: $1.69
Low: $1.25
High: $2.36

2 Week Range

Now: $1.85
Low: $1.23
High: $9.14

Volume

240,573 shs

Average Volume

227,625 shs

Market Capitalization

$69.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A